[CFRX] ContraFect Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 77.83 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.25 Change: 0.1 (4.65%)
Ext. hours: Change: 0 (0%)

chart CFRX

Refresh chart

Strongest Trends Summary For CFRX

CFRX is in the medium-term down -81% in 1 year. In the long-term down -89% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding27.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV3.54 Price/Cash Per Share
Price/Free Cash Flow ROA-117.7% ROE-141.17% ROI
Current Ratio6.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.17
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit-4.49 M Operating Profit-4.7 M Total Assets25.31 M Total Current Assets23.15 M
Total Current Liabilities3.68 M Total Debt Total Liabilities4.21 M Total Revenue
Technical Data
High 52 week2.82 Low 52 week0.36 Last close0.49 Last change1.22%
RSI48.54 Average true range0.06 Beta0.54 Volume23.29 K
Simple moving average 20 days-5.58% Simple moving average 50 days0.82% Simple moving average 200 days-61.73%
Performance Data
Performance Week-4.69% Performance Month-16.97% Performance Quart11.34% Performance Half-76.56%
Performance Year-74.62% Performance Year-to-date-67.98% Volatility daily5.75% Volatility weekly12.86%
Volatility monthly26.36% Volatility yearly91.3% Relative Volume129.23% Average Volume1.13 M
New High New Low

News

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

2019-06-19 13:08:36 | Investors Who Bought ContraFect NASDAQ:CFRX Shares Three Years Ago Are Now Down 84%

2019-06-17 17:00:00 | ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data

2019-06-07 09:27:00 | Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

2019-06-06 07:00:00 | ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296

2019-06-03 07:00:00 | ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium

2019-05-31 07:00:00 | ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

2019-05-20 10:15:00 | CFRX: R&D Symposium Highlights Positive Data for Exebacase…

2019-05-10 07:19:21 | ContraFect: 1Q Earnings Snapshot

2019-05-10 07:00:00 | ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-08 07:00:00 | ContraFect to Host R&D Symposium on Direct Lytic Agents Lysins and Amurins with Clinical Thought Leaders on Infectious Disease

2019-04-30 10:30:00 | CFRX: Additional Phase 2 Data Presented at ECCMID…

2019-04-16 05:15:00 | ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-13 09:38:23 | The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

2019-04-12 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-08 07:00:00 | ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

2019-04-04 07:00:00 | ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-02 07:00:00 | ContraFect Announces CEO Transition

2019-03-21 07:00:00 | ContraFect to Present at the Bacteriophage Therapy Summit

2019-03-20 10:30:00 | CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…

2019-03-14 08:01:44 | ContraFect: 4Q Earnings Snapshot

2019-03-14 07:00:00 | ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-13 07:00:00 | ContraFect to Present at the Oppenheimer 29th Annual Healthcare Conference

2019-03-04 07:00:00 | ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

2019-02-25 07:00:00 | Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors CFRX

2019-02-13 07:00:00 | ContraFect Announces Oral Presentation at the 2019 Gordon Research Conference on Mechanisms and Application: Realizing the Potential of Antimicrobial Host Defense Peptides for Human and Veterinary Medicine

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2019-01-17 09:26:00 | These 4 Healthcare Stocks Are Raising Expectations

2019-01-17 07:00:00 | ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

2019-01-09 09:45:00 | CFRX: Exebacase Improves Clinical Outcomes in Phase 2 Trial…

2019-01-07 07:00:00 | ContraFect’s Exebacase CF-301 Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

2018-12-23 10:22:03 | Is ContraFect Corp CFRX A Good Stock To Buy?

2018-12-20 17:00:00 | ContraFect to Present at Biotech Showcase 2019

2018-11-19 07:00:00 | ContraFect to Present at Piper Jaffray Health Care Conference

2018-11-16 07:50:00 | Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

2018-11-12 09:15:00 | CFRX: Waiting on Data from Phase 2 Study of CF-301…

2018-11-12 07:00:00 | ContraFect Appoints Michael Messinger as Chief Financial Officer

2018-11-08 09:59:21 | ContraFect: 3Q Earnings Snapshot

2018-11-08 07:00:00 | ContraFect Announces Third Quarter 2018 Financial Results

2018-11-01 07:00:00 | ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes

2018-10-22 17:00:00 | ContraFect to Participate in World Antimicrobial Resistance Congress 2018

2018-09-25 07:00:00 | ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 exebacase at IDWeek 2018

2018-09-24 09:30:00 | CFRX: Enrollment for Phase 2 Trial of CF-301 Complete; Data in 4Q18…

2018-09-20 17:00:00 | ContraFect to Present at Two Upcoming Investor Conferences

2018-09-06 08:30:00 | ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 exebacase in Patients with Staphylococcus Aureus Bacteremia

2018-08-29 17:30:00 | ContraFect to Present at Two Upcoming Investor Conferences

2018-08-14 17:00:00 | ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

2018-08-13 12:15:00 | CFRX: Data from Phase 2 Trial of CF-301 in 4Q18…

2018-08-09 07:35:44 | ContraFect: 2Q Earnings Snapshot

2018-08-09 07:00:00 | ContraFect Announces Second Quarter 2018 Financial Results